VictoryShares Developed Enh Vol Wtd ETF (CIZ) Reaches $35.27 Formed H&S; Abeona Therapeutics Inc. (ABEO) Covered By 11 Bulls

Abeona Therapeutics Inc. (NASDAQ:ABEO) Logo

Among 11 analysts covering Abeona Therapeutics (NASDAQ:ABEO), 11 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Abeona Therapeutics had 48 analyst reports since December 16, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Thursday, June 1 by Jefferies. The firm has “Buy” rating given on Wednesday, April 20 by Rodman & Renshaw. The firm earned “Buy” rating on Monday, January 29 by Cantor Fitzgerald. The rating was maintained by Jefferies on Friday, September 22 with “Buy”. The stock of Abeona Therapeutics Inc. (NASDAQ:ABEO) earned “Buy” rating by Cantor Fitzgerald on Wednesday, February 7. The rating was initiated by Jefferies with “Buy” on Friday, January 6. The firm has “Buy” rating given on Thursday, February 1 by H.C. Wainwright. On Thursday, September 14 the stock rating was initiated by RBC Capital Markets with “Buy”. The rating was maintained by Cantor Fitzgerald on Tuesday, May 15 with “Buy”. The rating was maintained by H.C. Wainwright with “Buy” on Monday, October 9. See Abeona Therapeutics Inc. (NASDAQ:ABEO) latest ratings:

05/06/2018 Broker: H.C. Wainwright Rating: Buy New Target: $30.0000 Maintain
05/06/2018 Broker: Seaport Global Rating: Buy New Target: $29.0000 Initiate
29/05/2018 Broker: H.C. Wainwright Rating: Buy New Target: $30.0000 Maintain
22/05/2018 Broker: Jefferies Rating: Buy New Target: $28.0000 Maintain
21/05/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $36.0000 Maintain
15/05/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $36.0000 Maintain
14/05/2018 Broker: H.C. Wainwright Rating: Buy New Target: $30.0000 Maintain
03/05/2018 Broker: H.C. Wainwright Rating: Buy New Target: $30.0000 Maintain
20/04/2018 Broker: H.C. Wainwright Rating: Buy New Target: $30.0000 Maintain
12/04/2018 Broker: H.C. Wainwright Rating: Buy New Target: $30.0000 Maintain

VictoryShares Developed Enh Vol Wtd ETF (CIZ) formed H&S with $32.45 target or 8.00% below today’s $35.27 share price. VictoryShares Developed Enh Vol Wtd ETF (CIZ) has $180.76M valuation. The ETF increased 0.23% or $0.08 during the last trading session, reaching $35.27. About 12,107 shares traded. VictoryShares Developed Enh Vol Wtd ETF (NASDAQ:CIZ) has risen 8.10% since June 12, 2017 and is uptrending. It has underperformed by 4.47% the S&P500.

The stock decreased 2.46% or $0.4 during the last trading session, reaching $15.85. About 576,686 shares traded. Abeona Therapeutics Inc. (NASDAQ:ABEO) has risen 191.23% since June 12, 2017 and is uptrending. It has outperformed by 178.66% the S&P500. Some Historical ABEO News: ; 02/04/2018 – ABEONA THERAPEUTICS INC – THIEL MOST RECENTLY SERVED AS EXECUTIVE VICE PRESIDENT AND CHIEF COMMERCIAL OFFICER OF ALEXION PHARMACEUTICALS, INC; 15/05/2018 – Castle Hook Partners LP Exits Position in Abeona Therapeutics; 02/04/2018 – ABEONA THERAPEUTICS NAMES CARSTEN THIEL, PH.D., AS CEO; 18/05/2018 – ABEONA THERAPEUTICS- RESULTS FROM PHASE 1/2 CLINICAL TRIAL FOR ABO-102 SHOW DURABLE BIOPHYSICAL REDUCTIONS OF DISEASE BURDEN; 17/05/2018 – Abeona Reports Update from EB-101 Gene Therapy in Epidermolysis Bullosa at 21st Annual ASGCT Meeting; 22/04/2018 – DJ Abeona Therapeutics Inc, Inst Holders, 1Q 2018 (ABEO); 02/04/2018 – ABEONA THERAPEUTICS – TIMOTHY J. MILLER WILL REMAIN PRESIDENT AND ASSUME POSITION OF CHIEF SCIENTIFIC OFFICER; 15/03/2018 Abeona Therapeutics Receives FDA Rare Pediatric Disease Designation for ABO-202 Gene Therapy Program in CLN1 Disease; 16/03/2018 – Abeona Therapeutics 4Q Loss/Shr 19c; 08/05/2018 – Abeona Therapeutics Announces Upcoming Presentations

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy and plasma products for severe and life-threatening rare diseases. The company has market cap of $749.79 million. The companyÂ’s lead programs are ABO-101, an adeno-associated virus based gene therapies for Sanfilippo syndrome type B; and ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A. It currently has negative earnings. It is also developing EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); EB-201 for for epidermolysis bullosa (EB); ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; ABO-301, an AAV gene therapy for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9 gene editing approach to gene therapy program for rare blood diseases.

More news for Abeona Therapeutics Inc. (NASDAQ:ABEO) were recently published by: Crainscleveland.com, which released: “Abeona Therapeutics opens The Elisa Linton Center for Rare Disease Therapies” on June 11, 2018. Seekingalpha.com‘s article titled: “Abeona Therapeutics: What The Latest Data For ABO-102 Foretells?” and published on May 29, 2018 is yet another important article.

Abeona Therapeutics Inc. (NASDAQ:ABEO) Ratings Chart